[@hubermanlab] How Mitochondria Control Your Metabolism | Dr. Jared Rutter

Link: https://youtu.be/bv56Cuq-fyY

Duration: 123 min

Transcript: Download plain text

Short Summary

In this Huberman Lab interview, Dr. Jared Ruer — a University of Utah biochemist and Howard Hughes Medical Institute investigator who is a world expert on mitochondria — explains how cells decide whether to burn fuel for ATP or divert it into biomass, using pyruvate and the mitochondrial pyruvate carrier (MPC) as the key pivot. He links misallocation of these resources to cancer, heart failure, and inflammatory disease, describes his lab's 2012 discovery of MPC1/MPC2, and argues that future cancer treatment will rely on combination therapies modeled on HIV triple therapy, tailored to each tumor's unique mutational and metabolic landscape.

Key Quotes

1. "Mitochondria are believed to have been the result of an endo symbiotic event where a bacterium a free-living bacterium was engulfed by another cell and in a way kind of domesticated." (00:09:18)
2. "And the reasons for for that are to some extent clear but I think largely unclear but that is definitely a feature of the aging process. You know there there is this sort of aspect of accumulation of damage." (00:07:03)
3. "what we get out of the food that we eat. Energy or building blocks that can be used to make a new cell to repair a cell that's been damaged for a B cell and immune cell that are the ones that make antibodies." (00:35:35)
4. "if glucose is too low you die within minutes if not seconds and that I think for a few different reasons but probably the most important one is the brain requires some amount of uh glucose to keep it functioning." (00:58:11)
5. "Basically, the form that energy takes when it's extracted from the food we eat and before it's converted to ATP is powering the mitochondria. And when that mitochondria is overpowered, that leads to a state that is very susceptible to generation of these reactive species that end up damaging our genome, creating mutations and damaging proteins and creating many of the problems that we see." (00:00:00)

Detailed Summary

Guest Background and Lab Context

Dr. Jared Ruer is a professor of biochemistry at the University of Utah and a Howard Hughes Medical Institute investigator, introduced as one of the world's leading experts on mitochondria and metabolism. The interview is hosted by Andrew Huberman on the Huberman Lab podcast, with conversation spanning cellular metabolism, disease, and therapeutic strategy.

• Dr. Ruer's lab discovered the mitochondrial pyruvate carrier proteins MPC1 and MPC2, published in 2012, after the carrier's existence had been inferred for roughly 60–70 years.
• Research leading to the discovery began around 2008–2009 and required triangulation across yeast, Drosophila, and human cell models, because no single organism would have been sufficient to identify the carrier proteins.
• The MPC work was done in collaboration with Carl Thummel (a fly geneticist) and was published simultaneously with an independent paper from Jean-Claude Martinou's lab in Geneva.
• The University of Utah is also home to Nobel laureate Mario Capecchi, who engineered the MPC knockout mice used in subsequent studies.

Mitochondrial Origins and Inheritance

Mitochondria originated from an ancient endosymbiotic event in which a free-living bacterium was engulfed by another cell, integrated into the host genome, and transmitted via the germ line. This event gave rise to all complex eukaryotic life, including plants, animals, and fungi.

• Mitochondria retain their own separate circular genome, a relic of their bacterial ancestor, distinct from the linear chromosomes in the nucleus.
• Mitochondrial DNA is inherited exclusively from the mother because sperm cytoplasm does not enter the egg upon fertilization — only the sperm's genome is delivered.
• A widely held (though not universal) hypothesis links mitochondria overloaded with excess energy to reactive oxygen species (ROS) that damage proteins, nucleic acids, and the genome.

Cellular Metabolism as a Foundational Concept

The body's metabolism is the sum total of metabolism across roughly 30 trillion individual cells, each with its own metabolic state that collectively defines overall health. Aging is fundamentally a cellular phenomenon driven by accumulated processes at the level of individual cells.

• A healthy cardiomyocyte uses about 65% of its energy just to keep pumping, with the rest allocated to self-maintenance and other pathways.
• Mitochondria distribute spatially throughout cells: in neurons with one-meter-long projections they transit to nerve terminals to power neurotransmission, and in crawling immune cells they congregate at the leading edge.
• By one's 50s, cells are a mosaic of original genetic makeup plus accumulated mutations.
• Huberman describes the body as a "constellation of microactories," arguing metabolism should be understood as many cell-specific metabolisms rather than a single organism-wide metabolism.

Cell-Type-Specific Mitochondrial Diversity

Mitochondria are not interchangeable across cell types; different cells have specialized mitochondria matched to their primary function. Some cells prioritize biomass production for duplication, while others prioritize ATP generation for continuous work.

• Cardiomyocytes primarily need ATP for continuous contraction and turn over very little, while gut-lining stem cells need biomass-producing mitochondria and duplicate every 5–7 days.
• Work by Craig Thompson at Memorial Sloan Kettering has shown that a single cell can contain two distinct kinds of mitochondria, one more biosynthetic (producing biomass) and one more energy-extracting (producing ATP).
• In cardiomyocytes, 70–80% of energy extraction comes from fat, especially under fasted conditions, while the brain preferentially consumes glucose (and can run on ketones).
• The heart is metabolically omnivorous, able to use fats, glucose, lactate, ketones, and amino acids as fuels.
• Activated B cells converting into antibody-producing cells need amino acids to make proteins (antibodies), exemplifying biomass-driven metabolism in immune function.

Fed vs. Fasted Hormonal Context

Hormonal signaling tells cells how much substrate is available and how to allocate it. The body shifts between fed and fasted metabolic states via hormones whose magnitude acts as a graded signal of substrate availability.

• After eating, digestion releases sugars, amino acids, and fats, triggering hormones like GLP-1 and insulin to signal a fed state.
• Insulin acts not just as a glucose shuttle but as a graded signal whose magnitude tells cells how much substrate is available, informing allocation decisions.
• During fasting, glucagon triggers fat release from adipocytes; stored fat in adipocytes enabled human ancestors to survive prolonged fasting.
• Glucagon biology is now being combined with GLP-1 drugs in some newer obesity therapies.

Pyruvate and the Burn-vs-Build Decision

Glucose enters cells and is broken down by glycolysis into pyruvate — a six-carbon sugar converted to a three-carbon molecule. Pyruvate sits at a critical pivot that determines whether a cell burns fuel for ATP or diverts it into biomass for new cell components.

• Intestinal stem cells do not burn pyruvate for ATP; instead they convert it into biomass to support turnover roughly every 5–7 days.
• Pyruvate can be converted to lactate when oxygen is unavailable, preserving carbon for biosynthesis — as occurs during the muscle burn of intense exercise.
• Cells prioritize burning free fatty acids because excess free fatty acids are acutely toxic and can disrupt cellular structures, whereas excess glucose is more chronically dangerous.
• Excess lactate can cause lactic acidosis, which can be lethal due to disrupted cellular chemistry.

MPC Discovery and Function

The Mitochondrial Pyruvate Carrier (MPC) sits in the mitochondrial membrane and provides the pore that allows pyruvate to enter mitochondria for ATP production. Its protein identity was unknown for decades despite clear evidence of its function.

• The MPC1/MPC2 discovery was published in 2012, with research dating to around 2008–2009, in collaboration with Carl Thummel.
• The two proteins are conserved across yeast, plants, and animals.
• Ruer's lab started by studying uncharacterized mitochondrial proteins; two of these turned out to be MPC1 and MPC2.
• Triangulation across yeast, fruit fly, and human cell models was necessary because no single organism would have sufficed to identify the carrier.

MPC Knockout Phenotypes and Disease

Removing MPC produces striking, disease-mirroring phenotypes that reveal the consequences of misallocated pyruvate. These genetic experiments show that pathology arises not from energy deficit but from misallocation of resources.

• Whole-body MPC knockout mice, engineered by Nobel laureate Mario Capecchi, die in utero around embryonic day 12–13 of a ~19–20 day mouse gestation.
• Heart-specific MPC knockout mice survive for weeks but die of heart failure with a massively enlarged heart.
• The heart-specific knockouts do not die from ATP deficiency — they still burn fatty acids — but from a pathological resource allocation switch in which cardiomyocytes divert glucose to biomass and growth instead of efficient ATP production.
• This mirrors human heart failure, in which nearly every patient ends up with a big, dilated, less-effective pumping heart.
• The heart-specific MPC knockout work was initiated by Ahmed Clinton (former postdoc, now running his own lab at Rutgers).
• Aberrant biomass production is implicated in cancer, pathologically enlarged hearts, and hyperactivated immune cells driving inflammatory diseases.

Lactate Metabolism

Pyruvate can be diverted to lactate under low-oxygen conditions, but lactate itself is now understood as a major circulating fuel. Lactate biology has implications for exercise, brain function, and cardiovascular health.

• Joshua Rabinowitz at Princeton has shown that lactate is itself an important fuel, with the heart being particularly good at consuming it.
• Intense aerobic exercise generates lactate that may signal the brain to produce BDNF, supporting the formation of new neural connections.
• Humans produce lactate, not lactic acid, a distinction Andy Galpin previously emphasized on the podcast.
• High circulating lactate causes lactic acidosis, which can be lethal due to disrupted cellular chemistry.

Cancer as Resource Allocation and the Warburg Effect

Cancer is reframed as a resource-allocation problem in which transformed cells prioritize building new cellular components over efficient energy production. The famous Warburg effect, originally interpreted as broken mitochondria, is now understood as highly effective biosynthetic mitochondria.

• The Warburg effect is named after Otto Warburg, who observed in the 1920s that cancer cells consume less oxygen than surrounding cells.
• Warburg originally interpreted low oxygen consumption as evidence that mitochondria in cancer cells are broken.
• Modern interpretation is that cancer mitochondria are not broken but are very effective at producing biosynthetic building materials needed for tumor duplication.
• FDG PET imaging exploits the fact that tumors take up large amounts of glucose, making it useful for cancer diagnosis.
• A tumor arises when a single transformed cell shifts resources toward duplication over function, prioritizing biomass over efficient ATP generation.
• Cancers ultimately kill the host, which is not a good long-term survival strategy for the cancer.
• Tasmanian devils have transmissible cancers spread through bite wounds, illustrating the unusual evolutionary dynamics of cancer.
• Cancer development is described as an evolutionary process in a single host, distinct from viral evolution that spreads between hosts.

Drug Resistance and Combination Therapy

Tumors evolve under the selective pressure of cancer drugs, so single-agent therapy almost always fails. The argument is made that the future of cancer treatment lies in tailored combination therapies modeled on HIV triple-combination treatment.

• A drug killing 99.9% of tumor cells leaves 0.1% resistant cells that can repopulate into a drug-resistant tumor.
• Even a single resistant cancer cell with the right mutation can theoretically regrow a tumor that is now resistant to the original drug.
• Cancer cells can develop resistance to metabolism-targeted therapies by mutating and rewiring their metabolism to build the same thing a different way.
• Checkpoint inhibitors such as PD1 and PDL1 inhibitors have been a major advance over the last 10–15 years, stripping the immune-evading cloak from cancer cells.
• KRAS-targeting drugs are a recent example of oncogenic-mutation-targeted therapies that hit only the cancer-driving proteins, though resistance can still emerge.
• Ruer argues cancer therapy will increasingly rely on safe, targeted drug combinations analogous to HIV triple-combination therapy, hitting different features of a tumor's unique biochemistry and approximating a cure.

Cancer Reclassification

Historical cancer classification by anatomical site (breast, liver, colon) is criticized as unhelpful because it obscures shared biology across tissue types. The proposal is to reclassify cancers by cellular phenotype rather than by anatomical address.

• Some breast cancers are more molecularly similar to certain liver cancers than to other breast cancers.
• Historical classification was based on anatomical location rather than underlying biology, a system defined by the surgeons who removed tumors.
• Each tumor has a unique mutational landscape that drives its ability to evade the immune system, propagate, and avoid cell death.
• Beyond mutations, the unique metabolism of a cancer cell is what enables the mutational instructions to be executed.
• Blocking cancer cells' resource allocation toward building new cells has been a major focus of the field for 10–15 years.
• The goal is to use a tumor's unique mutational landscape to identify drug combinations effective at killing that tumor's cells.

Repurposed Drugs and Fajgenbaum's Work

Dr. David Fajgenbaum of the University of Pennsylvania cured his own Castleman's disease by self-administering combinations of already approved drugs — work that has now been sustained for 11 years. His nonprofit extends the approach to other patients using AI and cell assays.

• Fajgenbaum runs the nonprofit Every Cure, which uses AI and cell assays to test approved drugs against patient tumor biopsies in desperate cases, with some cures and many life extensions reported.
• A highlighted finding from Fajgenbaum's work is that breast cancer surgeries using lidocaine are associated with significantly lower recurrence rates, possibly due to lidocaine's effects on the local environment.

Metabolic Imaging and Diagnostics

A key open question is identifying the single metabolic parameter (or collection of parameters) that best indicates whether a cell is healthy, and measuring it non-invasively. Existing imaging tools are improving, but a true cellular-resolution human metabolic map remains aspirational.

• An envisioned future diagnostic involves drinking a safe fluid, being imaged in a tube at ages 5 and 50, and getting a red/green metabolic map of every cell down to single-cell resolution.
• Imaging metabolism with cellular resolution in a human body remains a very difficult problem due to spatial resolution limits and the lack of any visually observable metabolic signal.
• Neuroscience imaging historically progressed from invasive electrode insertion and lesion studies, to fMRI based on oxygenated vs. deoxygenated blood, to 2-deoxyglucose glucose-uptake imaging with crude spatial and temporal resolution.
• Modern tools can now measure voltage and calcium signaling in the brain, marking improvement over earlier blood-flow-based methods.
• 2-deoxyglucose imaging allowed measurement of glucose uptake but had crude spatial resolution and poor time resolution.
• The entry of chemists, bioengineers, physicists, and computer scientists into biology enabled significantly better measurement capabilities inside cells.
• Experimental tools for measuring specific intermediates, products, and substrates of metabolism at individual locations within individual cells are improving rapidly.

Disease Detection via Scent and Breath

Human scent-based disease detection is plausible based on validated reports, and exhaled breath chemistry could provide a non-invasive window into systemic or cellular metabolic state.

• A woman was reportedly able to smell Parkinson's disease as a musky scent, and spouses (especially wives) of Parkinson's patients later recalled noticing that scent.
• Parents can detect illness in infants through stool or skin odor before the infants can communicate verbally.
• Exhaled breath chemistry could reflect systemic or even cellular metabolic state because altered metabolism produces different chemical compounds in different proportions, analogous to blood-chemistry diagnostics.

Energy Toxicity and ROS

The host introduces the concept of "energy toxicity," framing excess calories as causing downstream biochemical problems beyond simply excess body fat. Mitochondrial overload is hypothesized to drive damaging reactive oxygen species production.

• "Energy toxicity" was previously raised on the podcast by Dr. Lane Norton.
• Excess calories can cause downstream biochemical problems beyond simply excess body fat.
• A widely accepted (though not universal) hypothesis is that mitochondria overloaded with excess energy produce ROS that damage proteins, nucleic acids, and the genome, contributing to mutations and aging.
• The energy extracted from food before conversion to ATP is the form that powers mitochondria, and overpowering mitochondria makes them susceptible to generating damaging reactive species.

Closing Framing and Key Numbers

Each cell has its own metabolism whose health status collectively defines overall health, and understanding resource allocation is positioned as a frontier with therapeutic potential in heart failure, cancer, and inflammatory disease.

• "The body's metabolism is the sum total of the metabolism of each one of our roughly 30 trillion cells."
• Heart-failure MPC knockouts don't die from inability to make ATP — they die from pathological resource allocation toward biomass.
• The field is framed as being at the frontier of understanding and potentially therapeutically correcting resource-allocation decisions in heart failure and cancer.
• A central challenge of cancer therapy is that cancer cells are the body's own cells and lack antigens recognized as non-self by the immune system, so killing them risks killing healthy cells.
• Targeting stem-cell pathways risks damaging normal stem cells such as those that regenerate the gut lining, contributing to chemotherapy side effects.
• The host asks whether reallocating pyruvate use could be a druggable target via gene therapy, ultrasound, or light, framing interventions as mechanical or chemical forces.
• The body's two ways to change things are mechanical and chemical forces — for example, gut distension vs. hypothalamic signaling for fullness.

Key Reference Numbers

• 30 trillion cells in the human body
• 70–80% of cardiomyocyte energy from fat
• Healthy cardiomyocytes use ~65% of energy just to keep pumping
• Gut lining turns over every 5–7 days
• Mouse gestation ~19–20 days; MPC knockout embryos die at day 12–13
• Heart-specific MPC knockouts die in weeks with enlarged hearts
• MPC1/MPC2 published in 2012, from research starting around 2008–2009
• 60–70 years of inference about MPC's existence before the proteins were identified
• PD1/PDL1 checkpoint inhibitors have been a major advance over the last 10–15 years
• 99.9% tumor kill still leaves 0.1% resistant cells capable of repopulation